Revision as of 14:52, 9 June 2020 editIk pachpadra (talk | contribs)11 edits →ReferencesTags: Mobile edit Mobile web edit← Previous edit | Latest revision as of 21:10, 19 November 2024 edit undoMSLQr (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers3,749 editsm Reverted edits by 116.255.53.21 (talk) (AV)Tags: AntiVandal Rollback | ||
(36 intermediate revisions by 24 users not shown) | |||
Line 1: | Line 1: | ||
{{ |
{{Short description|Muscular disease in which the muscle fibers do not function correctly}} | ||
{{Use dmy dates|date=April 2022}} | |||
{{Infobox medical condition (new) | {{Infobox medical condition (new) | ||
| name |
| name = Myopathy | ||
| image |
| image = | ||
| caption |
| caption = | ||
| field |
| field = ], ] | ||
| symptoms |
| symptoms = | ||
| complications |
| complications = | ||
| onset |
| onset = | ||
| duration |
| duration = | ||
| causes |
| causes = | ||
| risks |
| risks = | ||
| diagnosis |
| diagnosis = | ||
| differential |
| differential = | ||
| prevention |
| prevention = | ||
| treatment |
| treatment = | ||
| medication |
| medication = | ||
| prognosis |
| prognosis = | ||
| frequency |
| frequency = | ||
| deaths |
| deaths = | ||
| synonym = Muscle disease | |||
}} | }} | ||
In ], '''myopathy''' is a ] of the ]<ref name="urlMyopathy - Definition from the Merriam-Webster Online Dictionary">{{cite web |url=http://www.merriam-webster.com/dictionary/Myopathy |title=Myopathy - Definition from the Merriam-Webster Online Dictionary |
In ], '''myopathy''' is a ] of the ]<ref name="urlMyopathy - Definition from the Merriam-Webster Online Dictionary">{{cite web |url=http://www.merriam-webster.com/dictionary/Myopathy |title=Myopathy - Definition from the Merriam-Webster Online Dictionary }}</ref> in which the ]s do not function properly. ''Myopathy'' means '''muscle disease''' (] : myo- ''muscle'' + patheia '']'' : ''suffering''). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("]" or "]" disorders) or elsewhere (e.g., the brain). | ||
This muscular defect typically results in ] (muscle pain), ] (reduced muscle force), or premature ] (initially normal, but declining muscle force). ]s, ], ], and ] can also be associated with myopathy. Myopathy experienced over a long period (chronic) may result in the muscle becoming an abnormal size, such as ] (abnormally small) or a ] (abnormally large). | |||
'''Muscular disease''' can be classified as ] or ] in nature. Some conditions, such as ], can be considered both neuromuscular and musculoskeletal. | |||
Capture myopathy can occur in wild or captive animals, such as deer and ], and leads to morbidity and mortality.<ref>{{cite journal | vauthors = Green-Barber JM, Stannard HJ, Old JM | title = A suspected case of myopathy in a free-ranging eastern grey kangaroo (''Macropus giganteus'') | journal = Australian Mammalogy | volume = 40 | pages = 122–126 | date = 2018 | doi = 10.1071/AM16054 }}</ref> It usually occurs as a result of stress and physical exertion during capture and restraint. | |||
Muscular disease can be classified as ] or ] in nature. Different myopathies may be inherited, infectious, non-communicable, or idiopathic (cause unknown). The disease may be isolated to affecting only muscle (pure myopathy), or may be part of a systemic disease as is typical in ]. | |||
==Signs and symptoms== | ==Signs and symptoms== | ||
Common symptoms include muscle weakness, |
Common symptoms include muscle weakness, cramps, stiffness, and ].{{citation needed|date=October 2020}} | ||
== Systemic diseases == | == Systemic diseases == | ||
Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, collagen related,<ref name="pmid19557868">{{cite journal | vauthors = Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG | title = Neuromuscular involvement in various types of Ehlers-Danlos syndrome | journal = Ann. Neurol. | volume = 65 | issue = 6 | pages = 687–97 | date = June 2009 | pmid = 19557868 | doi = 10.1002/ana.21643 }}</ref> and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Most of the inflammatory myopathies can have a chance association with malignant lesion; the incidence appears to be specifically increased only in patients with dermatomyositis.<ref name="pmid21886637">{{cite journal | vauthors = Chawla J | title = Stepwise approach to myopathy in systemic disease | journal = Front Neurol | volume = 2 |
Myopathies in systemic disease results from several different disease processes including ], ], ], infectious, drug- and toxin-induced, critical illness myopathy, metabolic, ] related,<ref name="pmid19557868">{{cite journal | vauthors = Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG | title = Neuromuscular involvement in various types of Ehlers-Danlos syndrome | journal = Ann. Neurol. | volume = 65 | issue = 6 | pages = 687–97 | date = June 2009 | pmid = 19557868 | doi = 10.1002/ana.21643 | s2cid = 22600065 }}</ref> and myopathies with other systemic disorders. Patients with systemic myopathies often present ] or sub acutely. On the other hand, ] or ] generally present in a ] fashion with exceptions of ] where symptoms on occasion can be precipitated acutely. Metabolic myopathies, which affect the production of ATP within the muscle cell, typically present with ] (exercise-induced) rather than static symptoms.<ref>{{Cite journal |last1=Darras |first1=Basil T. |last2=Friedman |first2=Neil R. |date=February 2000 |title=Metabolic myopathies: a clinical approach; part I |url=https://linkinghub.elsevier.com/retrieve/pii/S0887899499001332 |journal=Pediatric Neurology |language=en |volume=22 |issue=2 |pages=87–97 |doi=10.1016/S0887-8994(99)00133-2|pmid=10738913 }}</ref> Most of the ] can have a chance association with malignant lesion; the incidence appears to be specifically increased only in patients with dermatomyositis.<ref name="pmid21886637">{{cite journal | vauthors = Chawla J | title = Stepwise approach to myopathy in systemic disease | journal = Front Neurol | volume = 2 | pages = 49 | date = 2011 | pmid = 21886637 | pmc = 3153853 | doi = 10.3389/fneur.2011.00049 | doi-access = free }}</ref> | ||
There are many types of myopathy. ] codes are provided here where available. | There are many types of myopathy. ] codes are provided here where available. | ||
===Inherited forms=== | ===Inherited forms=== | ||
* (G71.0) ] (or |
* (G71.0) ] (or muscular dystrophies) are a subgroup of myopathies characterized by muscle degeneration and regeneration. Clinically, muscular dystrophies are typically progressive, because the muscles' ability to regenerate is eventually lost, leading to progressive weakness, often leading to use of a ], and eventually death, usually related to ] weakness. | ||
* (G71.1) ] | * (G71.1) ] | ||
** ] | ** ] | ||
Line 40: | Line 46: | ||
** (G71.2) ] (characterized by presence of "nemaline rods" in the muscle), | ** (G71.2) ] (characterized by presence of "nemaline rods" in the muscle), | ||
** (G71.2) ] (characterized by multiple small "cores" or areas of disruption in the muscle fibers), | ** (G71.2) ] (characterized by multiple small "cores" or areas of disruption in the muscle fibers), | ||
** (G71.2) ] (or |
** (G71.2) ] (or myotubular myopathy) (in which the ] are abnormally found in the center of the muscle fibers), a rare muscle ] disorder | ||
* (G71.3) ], which are due to defects in ], which provide a critical source of energy for muscle | * (G71.3) ], which are due to defects in ], which provide a critical source of energy for muscle | ||
* (G72.3) |
* (G72.3) Familial ] | ||
* (G72.4) ], which are caused by problems with the immune system attacking components of the muscle, leading to signs of ] in the muscle | * (G72.4) ], which are caused by problems with the immune system attacking components of the muscle, leading to signs of ] in the muscle | ||
* (G73.6) ], which result from defects in biochemical metabolism that primarily affect muscle | * (G73.6) ], which result from defects in biochemical metabolism that primarily affect muscle | ||
Line 50: | Line 56: | ||
** ] | ** ] | ||
** ] | ** ] | ||
** ] | ** ] | ||
** ] | ** ] | ||
** ] | ** ] | ||
** ] | ** ] | ||
** ] | ** ] | ||
Line 59: | Line 65: | ||
* (G72.0 - G72.2) External substance induced myopathy | * (G72.0 - G72.2) External substance induced myopathy | ||
** (G72.0) Drug-induced myopathy | ** (G72.0) Drug-induced myopathy | ||
*** ] myopathy is caused by this class of steroids ] of the muscle proteins leading to ].<ref name="pmid8049126">{{cite journal | vauthors = Seene T | title = Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy | journal = J. Steroid Biochem. Mol. Biol. | volume = 50 | issue = |
*** ] myopathy is caused by this class of steroids ] of the muscle proteins leading to ].<ref name="pmid8049126">{{cite journal | vauthors = Seene T | title = Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy | journal = J. Steroid Biochem. Mol. Biol. | volume = 50 | issue = 1–2 | pages = 1–4 | date = July 1994 | pmid = 8049126 | doi = 10.1016/0960-0760(94)90165-1 | s2cid = 27814895 }}</ref> | ||
** (G72.1) ] | ** (G72.1) ] | ||
** (G72.2) Myopathy due to other toxic agents - including atypical myopathy in ] caused by toxins in ] seeds and seedlings.<ref>{{cite web|url=https://www.rainbowequinehospital.co.uk/information-on-sycamore-poisoning/|title=Information On Sycamore Poisoning|publisher = Rainbow Equine Hospital|access-date=16 May 2017}}</ref><ref>{{cite web|url=http://www.rvc.ac.uk/equine-vet/news/equine-atypical-myopathy-toxin-and-biochemical-tests-and-tree-sample-testing-available-at-the-royal-veterinary-college|title=Equine Atypical Myopathy toxin and biochemical tests and tree sample testing available at the RVC|publisher= Royal Veterinary college - University of London|access-date=16 May 2017|date=13 February 2017}}</ref> | ** (G72.2) Myopathy due to other toxic agents - including ] in ] caused by toxins in ] seeds and seedlings.<ref>{{cite web|url=https://www.rainbowequinehospital.co.uk/information-on-sycamore-poisoning/|title=Information On Sycamore Poisoning|publisher = Rainbow Equine Hospital|access-date=16 May 2017}}</ref><ref>{{cite web|url=http://www.rvc.ac.uk/equine-vet/news/equine-atypical-myopathy-toxin-and-biochemical-tests-and-tree-sample-testing-available-at-the-royal-veterinary-college|title=Equine Atypical Myopathy toxin and biochemical tests and tree sample testing available at the RVC|publisher= Royal Veterinary college - University of London|access-date=16 May 2017|date=13 February 2017}}</ref> | ||
* (M33.0-M33.1) | * (M33.0-M33.1) | ||
**] produces muscle weakness and skin changes. The skin rash is reddish and most commonly occurs on the face, especially around the eyes, and over the knuckles and elbows. Ragged nail folds with visible capillaries can be present. It can often be treated by drugs like corticosteroids or immunosuppressants. (M33.2) | ** ] produces muscle weakness and skin changes. The skin rash is reddish and most commonly occurs on the face, especially around the eyes, and over the knuckles and elbows. Ragged nail folds with visible capillaries can be present. It can often be treated by drugs like corticosteroids or immunosuppressants. (M33.2) | ||
**] produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants. | ** ] produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants. | ||
**] is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known. | ** ] is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known. | ||
* (M60.9) ] | |||
* (M61) ] | * (M61) ] | ||
* (M62.89) ] and (R82.1) ]s | * (M62.89) ] and (R82.1) ]s | ||
Line 72: | Line 79: | ||
* ] | * ] | ||
===] / ] |
===] / ]=== | ||
* ({{ICD10|I|40||i|30}}) ] | * ({{ICD10|I|40||i|30}}) ] | ||
* ({{ICD10|I|41||i|30}}) ] in diseases classified elsewhere | * ({{ICD10|I|41||i|30}}) ] in diseases classified elsewhere | ||
Line 90: | Line 97: | ||
* ({{ICD10|I|43||i|30}}) ] in diseases classified elsewhere | * ({{ICD10|I|43||i|30}}) ] in diseases classified elsewhere | ||
<ref name="The Webs Free 2019 ICD-10-CM/PCS Medical Coding Reference 2018">{{cite web | title=2019 ICD-10-CM Diagnosis Code I42.9: Cardiomyopathy, unspecified | website=The Web's Free 2019 ICD-10-CM/PCS Medical Coding Reference | date=2018 |
<ref name="The Webs Free 2019 ICD-10-CM/PCS Medical Coding Reference 2018">{{cite web | title=2019 ICD-10-CM Diagnosis Code I42.9: Cardiomyopathy, unspecified | website=The Web's Free 2019 ICD-10-CM/PCS Medical Coding Reference | date=1 October 2018 | url=https://www.icd10data.com/ICD10CM/Codes/I00-I99/I30-I52/I42-/I42.9 | access-date=5 February 2019}}</ref> | ||
===Differential diagnosis |
===Differential diagnosis=== | ||
'''At birth''''' | '''At birth''''' | ||
* None as systemic causes; mainly hereditary | * None as systemic causes; mainly hereditary | ||
'''Onset in childhood''' | '''Onset in childhood''' | ||
* Inflammatory myopathies – dermatomyositis, polymyositis (rarely) | * Inflammatory myopathies – dermatomyositis, polymyositis (rarely) | ||
* Infectious myopathies | * Infectious myopathies | ||
Line 105: | Line 110: | ||
'''Onset in adulthood'''<ref name="pmid21886637"/> | '''Onset in adulthood'''<ref name="pmid21886637"/> | ||
* Inflammatory myopathies – polymyositis, dermatomyositis, inclusion body myositis, viral (HIV) | * Inflammatory myopathies – polymyositis, dermatomyositis, inclusion body myositis, viral (HIV) | ||
* Infectious myopathies | * Infectious myopathies | ||
Line 115: | Line 119: | ||
==Treatments== | ==Treatments== | ||
Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. ], ], bracing for support, ], and massage are all current treatments for a variety of myopathies. | Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. ], ], bracing for support, ], and massage are all current treatments for a variety of myopathies.{{citation needed|date=October 2020}} | ||
==References== | ==References== | ||
{{Reflist}} | |||
{{reflist}}https://balotara.in/ | |||
==External links== | ==External links== | ||
{{Medical condition classification and resources | |||
| DiseasesDB = 8723 | |||
| ICD10 = {{ICD10|G|71||g|70}}-{{ICD10|G|72||g|70}}, {{ICD10|M|60||m|60}}-{{ICD10|M|63||m|60}} | |||
| ICD9 = {{ICD9|359.4}}-{{ICD9|359.9}}, {{ICD9|728}}-{{ICD9|728}} | |||
| ICDO = | |||
| MedlinePlus = | |||
| eMedicineSubj = emerg | |||
| eMedicineTopic = 328 | |||
| MeshID = D009135 | |||
}} | |||
* | * | ||
*See http://neuromuscular.wustl.edu/ for medical descriptions. | * See http://neuromuscular.wustl.edu/ for medical descriptions. | ||
{{Diseases of myoneural junction and muscle}} | {{Diseases of myoneural junction and muscle}} | ||
{{Systemic connective tissue disorders}} | {{Systemic connective tissue disorders}} | ||
{{Myopathy}} | {{Myopathy}} | ||
{{Authority control}} | |||
] | ] |
Latest revision as of 21:10, 19 November 2024
Muscular disease in which the muscle fibers do not function correctlyMedical condition
Myopathy | |
---|---|
Other names | Muscle disease |
Specialty | Rheumatology, Neuromuscular medicine |
In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. Myopathy means muscle disease (Greek : myo- muscle + patheia -pathy : suffering). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("neuropathies" or "neurogenic" disorders) or elsewhere (e.g., the brain).
This muscular defect typically results in myalgia (muscle pain), muscle weakness (reduced muscle force), or premature muscle fatigue (initially normal, but declining muscle force). Muscle cramps, stiffness, spasm, and contracture can also be associated with myopathy. Myopathy experienced over a long period (chronic) may result in the muscle becoming an abnormal size, such as muscle atrophy (abnormally small) or a pseudoathletic appearance (abnormally large).
Capture myopathy can occur in wild or captive animals, such as deer and kangaroos, and leads to morbidity and mortality. It usually occurs as a result of stress and physical exertion during capture and restraint.
Muscular disease can be classified as neuromuscular or musculoskeletal in nature. Different myopathies may be inherited, infectious, non-communicable, or idiopathic (cause unknown). The disease may be isolated to affecting only muscle (pure myopathy), or may be part of a systemic disease as is typical in mitochondrial myopathies.
Signs and symptoms
Common symptoms include muscle weakness, cramps, stiffness, and tetany.
Systemic diseases
Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, collagen related, and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Metabolic myopathies, which affect the production of ATP within the muscle cell, typically present with dynamic (exercise-induced) rather than static symptoms. Most of the inflammatory myopathies can have a chance association with malignant lesion; the incidence appears to be specifically increased only in patients with dermatomyositis.
There are many types of myopathy. ICD-10 codes are provided here where available.
Inherited forms
- (G71.0) Dystrophies (or muscular dystrophies) are a subgroup of myopathies characterized by muscle degeneration and regeneration. Clinically, muscular dystrophies are typically progressive, because the muscles' ability to regenerate is eventually lost, leading to progressive weakness, often leading to use of a wheelchair, and eventually death, usually related to respiratory weakness.
- (G71.1) Myotonia
- (G71.2) The congenital myopathies do not show evidence for either a progressive dystrophic process (i.e., muscle death) or inflammation, but instead characteristic microscopic changes are seen in association with reduced contractile ability of the muscles. Congenital myopathies include, but are not limited to:
- (G71.2) nemaline myopathy (characterized by presence of "nemaline rods" in the muscle),
- (G71.2) multi/minicore myopathy (characterized by multiple small "cores" or areas of disruption in the muscle fibers),
- (G71.2) centronuclear myopathy (or myotubular myopathy) (in which the nuclei are abnormally found in the center of the muscle fibers), a rare muscle wasting disorder
- (G71.3) Mitochondrial myopathies, which are due to defects in mitochondria, which provide a critical source of energy for muscle
- (G72.3) Familial periodic paralysis
- (G72.4) Inflammatory myopathies, which are caused by problems with the immune system attacking components of the muscle, leading to signs of inflammation in the muscle
- (G73.6) Metabolic myopathies, which result from defects in biochemical metabolism that primarily affect muscle
- (G73.6/E74.0) Glycogen storage diseases, which may affect muscle
- (G73.6/E75) Lipid storage disorder
- (G72.89) Other myopathies
Acquired
- (G72.0 - G72.2) External substance induced myopathy
- (G72.0) Drug-induced myopathy
- Glucocorticoid myopathy is caused by this class of steroids increasing the breakdown of the muscle proteins leading to muscle atrophy.
- (G72.1) Alcoholic myopathy
- (G72.2) Myopathy due to other toxic agents - including atypical myopathy in horses caused by toxins in sycamore seeds and seedlings.
- (G72.0) Drug-induced myopathy
- (M33.0-M33.1)
- Dermatomyositis produces muscle weakness and skin changes. The skin rash is reddish and most commonly occurs on the face, especially around the eyes, and over the knuckles and elbows. Ragged nail folds with visible capillaries can be present. It can often be treated by drugs like corticosteroids or immunosuppressants. (M33.2)
- Polymyositis produces muscle weakness. It can often be treated by drugs like corticosteroids or immunosuppressants.
- Inclusion body myositis is a slowly progressive disease that produces weakness of hand grip and straightening of the knees. No effective treatment is known.
- (M60.9) Benign acute childhood myositis
- (M61) Myositis ossificans
- (M62.89) Rhabdomyolysis and (R82.1) myoglobinurias
The Food and Drug Administration is recommending that physicians restrict prescribing high-dose Simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage. The FDA drug safety communication stated that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy. "Simvastatin 80 mg should not be started in new patients, including patients already taking lower doses of the drug," the agency states.
Myocardium / cardio-myopathy
- (I40) Acute myocarditis
- (I41) Myocarditis in diseases classified elsewhere
- (I42) Cardiomyopathy
- (I42.0) Dilated cardiomyopathy
- (I42.1) Obstructive hypertrophy cardiomyopathy
- (I42.2) Other hypertrophic cardiomyopathy
- (I42.3) Endomyocardial (eosinophilic) disease
- (I42.4) Endocardial fibroelastosis
- (I42.5) Other restrictive cardiomyopathy
- (I42.6) Alcoholic cardiomyopathy
- (I42.8) Other cardiomyopathies
- (I43) Cardiomyopathy in diseases classified elsewhere
Differential diagnosis
At birth
- None as systemic causes; mainly hereditary
Onset in childhood
- Inflammatory myopathies – dermatomyositis, polymyositis (rarely)
- Infectious myopathies
- Endocrine and metabolic disorders – hypokalemia, hypocalcemia, hypercalcemia
Onset in adulthood
- Inflammatory myopathies – polymyositis, dermatomyositis, inclusion body myositis, viral (HIV)
- Infectious myopathies
- Endocrine myopathies – thyroid, parathyroid, adrenal, pituitary disorders
- Toxic myopathies – alcohol, corticosteroids, narcotics, colchicines, chloroquine
- Critical illness myopathy
- Metabolic myopathies
- Paraneoplastic myopathy
Treatments
Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. Drug therapy, physical therapy, bracing for support, surgery, and massage are all current treatments for a variety of myopathies.
References
- "Myopathy - Definition from the Merriam-Webster Online Dictionary".
- Green-Barber JM, Stannard HJ, Old JM (2018). "A suspected case of myopathy in a free-ranging eastern grey kangaroo (Macropus giganteus)". Australian Mammalogy. 40: 122–126. doi:10.1071/AM16054.
- Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG (June 2009). "Neuromuscular involvement in various types of Ehlers-Danlos syndrome". Ann. Neurol. 65 (6): 687–97. doi:10.1002/ana.21643. PMID 19557868. S2CID 22600065.
- Darras, Basil T.; Friedman, Neil R. (February 2000). "Metabolic myopathies: a clinical approach; part I". Pediatric Neurology. 22 (2): 87–97. doi:10.1016/S0887-8994(99)00133-2. PMID 10738913.
- ^ Chawla J (2011). "Stepwise approach to myopathy in systemic disease". Front Neurol. 2: 49. doi:10.3389/fneur.2011.00049. PMC 3153853. PMID 21886637.
- Seene T (July 1994). "Turnover of skeletal muscle contractile proteins in glucocorticoid myopathy". J. Steroid Biochem. Mol. Biol. 50 (1–2): 1–4. doi:10.1016/0960-0760(94)90165-1. PMID 8049126. S2CID 27814895.
- "Information On Sycamore Poisoning". Rainbow Equine Hospital. Retrieved 16 May 2017.
- "Equine Atypical Myopathy toxin and biochemical tests and tree sample testing available at the RVC". Royal Veterinary college - University of London. 13 February 2017. Retrieved 16 May 2017.
- "2019 ICD-10-CM Diagnosis Code I42.9: Cardiomyopathy, unspecified". The Web's Free 2019 ICD-10-CM/PCS Medical Coding Reference. 1 October 2018. Retrieved 5 February 2019.
External links
- GeneReviews/NCBI/NIH/UW entry on Myopathy with Deficiency of ISCU
- See http://neuromuscular.wustl.edu/ for medical descriptions.
Diseases of muscle, neuromuscular junction, and neuromuscular disease | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neuromuscular- junction disease | |||||||||||||||||||||||||||
Myopathy |
|
Systemic connective tissue disorders | |||||||||
---|---|---|---|---|---|---|---|---|---|
General |
| ||||||||
Other hypersensitivity/autoimmune | |||||||||
Other |